



Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

September 30, 2024

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- [Biora Therapeutics, Inc.](#) (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024.

Biora's submission was awarded a Presidential Poster Award by the ACG Abstract Selection Committee. Each year less than 5% of accepted abstracts receive this distinction for high quality, novel, unique, and interesting research. Details of the presentation are as follows:

Poster Number: P4275

Session Date: October 29, 2024 10:30 AM – 4:00 PM ET

Presenting Author: [Brian Feagan, MD, FRCPC](#)

All research presented at ACG 2024, including abstract titles, is strictly embargoed until Sunday, October 27 at 12:00 ET. A copy of the poster will be made available on [the Biora Therapeutics website](#) at the time of presentation.

About Biora Therapeutics

Biora Therapeutics is a clinical-stage biotech company developing two smart pill-based therapeutics platforms: the [NaviCap™ platform](#) for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the [BioJet™ platform](#) for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases.

For more information, visit [bioratherapeutics.com](#) or follow the company on [LinkedIn](#) or [X](#).

Safe Harbor Statement or Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model-based data projections for the BT-600 program, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "envision," "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "anticipate," "forward," "believe," "design," "estimate," "predict," "projects," "projecting," "potential," "plan," "goal(s)," "target," or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390

Media Contact

Liz Robinson
CG Life
lrobinson@cglife.com

